ClearVision Natoli

The Natoli Group - Clear Vision Research Lab

Our lab studies a number of retinal diseases, with our main focus on finding novel diagnostics and treatment options for Age-Related Macular Degeneration (AMD).

contact_support Contact
Associate Professor Riccardo Natoli
Group Leader

About

Image
ClearVision Natoli

If you were asked to identify the one sense that you cannot imagine life without, most peoples thoughts would immediate go to preservation of your sight. Our vision is the cornerstone of how we perceive and interact with the world and our environment. Yet, the grim reality is that without dedicated research aimed at preventing vision loss caused by retinal degenerations a staggering 1 in 7 individuals over the age of 50 will go blind from a currently uncurable retinal degeneration called Age-Related Macular Degeneration (AMD). The molecular and pathogenesis of AMD is similar to other neurodegenerative disorders, such as Dementia and Alzheimer’s, as is the underlying inflammatory aspect disease progression.

Under the leadership of Associate Professor Riccardo Natoli and along with his dynamic research team, our mission revolves around uncovering the root causes of retinal and neuronal degenerations, the very process that erodes the critical functionality of the retina and the brain. As neurons, including photoreceptors of the eye deteriorate with age understanding the molecular changes that occur as a consequence of neuronal cell loss will enable a better understanding of disease and enable the development of novel therapeutics and diagnostics.

Clear Vision Research Lab investigates various retinal diseases, including Retinopathy of Prematurity, Retinitis Pigmentosa, and Diabetic Retinopathy. However, it focus remains on pioneering innovative RNA and Extracellular Vesicle diagnostics and treatments s for Age-Related Macular Degeneration (AMD) and other neurodegenerative conditions. In Australia, AMD reigns as the leading cause of blindness, imposing an annual economic burden of approximately 5 billion dollars (source: Deloitte – Eyes on the Future, 2011). Alarming projections indicate that by 2040, a staggering 1.7 million Australians will grapple with vision loss stemming from AMD, with a global incidence of ~280 million.

The Natoli Group passionates about developing the next generation of vision researchers as indicated by the Clear Vision Research Initiative. This visionary initiative not only aids in funding the next generation of vision researchers through prestigious PhD scholarships, exemplified by the K.T. Tan Scholarship, but it also provides invaluable support to guide PhD students and Early-Career Researchers through the arduous transition from students to fully-fledged independent researchers. To delve deeper into this initiative, please visit the website: www.clearvisionresearch.com

The Natoli Group continually seek exceptional students to join their research family and contribute to groundbreaking projects outlined on this page. The Group relish the opportunity to engage with prospective students, tailoring projects to their unique talents and interests. If you are eager to immerse yourself in transformative research, please do not hesitate to reach out to Associate Professor Riccardo Natoli. Your journey towards groundbreaking discoveries in vision research starts here.

Awards

Publications

Projects

670nm Red Light as a treatment for Retinopathy of Prematurity (Phase 1 Clinical Trial)

Student intake

Open for Honours, PhD students

People

While there is no perfect model to simulate all the pathologies associated with human AMD, we use a growing number of approaches to better understand the progression of AMD and retinal degenerations in general. These models also serve to test the efficacy of novel AMD therapeutic and diagnostic pipelines.

Student intake

Open for Bachelor, Honours, Masters, PhD students

People

Exosomes are paramount to the pathogenesis of a plethora of neurodegenerative diseases but their role in retinal degenerations remains largely unknown. At the Clear Vision Research Lab we study exosomes using several miRNA-centered approaches.

Student intake

Open for Bachelor, Honours, Masters, PhD students

People

Despite only being discovered as recently as the turn of this century, miRNAs are already used in clinical trials as therapeutic candidates for complex diseases. Our research aims to characterise key miRNAs in the retina and exploit those as therapeutic molecules in the retina.

Student intake

Open for Bachelor, Honours, Masters, PhD students

People

We are exploring a number of therapeutic options, developed at ANU and by commercial partners, which include gene-based therapies, non-invasive therapeutics (including the use of low-level laser therapy using red light) and novel compounds.

Student intake

Open for Bachelor, Honours, Masters, PhD students

People

Optimising the dose of 670nm light therapy for treatment of retinal degenerations

Student intake

Open for students

People

Members

Leader

Riccardo Natoli

Group Leader - The Natoli Group

Researcher

Riemke Aggio-Bruce

Postdoctoral Fellow

Nathan Reynolds

Research Fellow

Ulrike Schumann

Research Fellow

Dr Jereme  Spiers

Research Fellow

Natasha Vassileff

Postdoctoral Fellow

Yvette Wooff

Research Fellow

Collaborator

Group Leader - The Valter Group

Student

News

ANU 3MT Final 2024 - Rakshanya and Sasanan

Creating a historic moment for the John Curtin School of Medical Research (JCSMR), two of our outstanding PhD students Sasanan and Rakshanya claimed the winner and runner-up awards at the Australian National University (ANU) 3-Minute Thesis Competition 2024 grand finale, held on 25 July at Llewellyn Hall.

Read the article
Riccardo Natoli Genevieve Bell VC-Awards-Ceremony-2023-2024

Associate Professor Riccardo Natoli has been recognised for his outstanding ability to mentor talented students and early career researchers with the Vice-Chancellors Award for Excellence in Supervision.

Read the article
Riccardo Natoli clear vision research erythrosight

Team ErythroSight seeks experts with pharmaceutical experience in therapeutic development and potential licensing deals for collaboration.

Read the article

Events

Justine Smith
-

Professor Justine Smith will present 'Drugging biologic targets in non-infectious uveitis’.

View the event